Tafasitamab and Lenalidomide as Second-Line Treatment in an Elderly Patient with a Primary Refractory Double-Hit Diffuse Large B-Cell Lymphoma
The phase II L-MIND study demonstrated that treatment with tafasitamab in combination with lenalidomide yielded high complete response rates in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Patients with primary refractory DLBCL relapsing within three months of frontlin...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2025-03-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2025.23.174 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849421077393965056 |
|---|---|
| author | Alexander Meisel Ziad Kassem Daniel Turek Tanja Angelina Gradistanac Tristan de Lage Christina Züger |
| author_facet | Alexander Meisel Ziad Kassem Daniel Turek Tanja Angelina Gradistanac Tristan de Lage Christina Züger |
| author_sort | Alexander Meisel |
| collection | DOAJ |
| description | The phase II L-MIND study demonstrated that treatment with tafasitamab in combination with lenalidomide yielded high complete response rates in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Patients with primary refractory DLBCL relapsing within three months of frontline therapy (later amended to six months) and double-hit lymphoma were excluded. In this case report, we present the clinical course of an 85-year-old woman with primary refractory, double-hit DLBCL who was successfully treated with tafasitamab plus lenalidomide following disease progression on the R-mini-CHOP regimen.
PEER REVIEWED ARTICLE
**Peer reviewers:**
Prof. Andreas Holbro, University Hospital Basel, Basel, Switzerland
Prof. Christoph Renner, Hospital Hirslanden, Zurich, Switzerland
Erik Aerts, Hematology Nurses & Healthcare Professionals Group, University Hospital Zurich, Zurich, Switzerland
Received on January 09, 2025; accepted after peer review on March 20, 2025; published online on March 23, 2025. |
| format | Article |
| id | doaj-art-742f4ff3b67b4960a335fa4066c23b28 |
| institution | Kabale University |
| issn | 2673-2092 2673-2106 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | THE HEALTHBOOK COMPANY LTD. |
| record_format | Article |
| series | healthbook TIMES. Oncology Hematology |
| spelling | doaj-art-742f4ff3b67b4960a335fa4066c23b282025-08-20T03:31:33ZengTHE HEALTHBOOK COMPANY LTD.healthbook TIMES. Oncology Hematology2673-20922673-21062025-03-0123110.36000/HBT.OH.2025.23.174Tafasitamab and Lenalidomide as Second-Line Treatment in an Elderly Patient with a Primary Refractory Double-Hit Diffuse Large B-Cell LymphomaAlexander MeiselZiad KassemDaniel TurekTanja Angelina GradistanacTristan de LageChristina ZügerThe phase II L-MIND study demonstrated that treatment with tafasitamab in combination with lenalidomide yielded high complete response rates in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Patients with primary refractory DLBCL relapsing within three months of frontline therapy (later amended to six months) and double-hit lymphoma were excluded. In this case report, we present the clinical course of an 85-year-old woman with primary refractory, double-hit DLBCL who was successfully treated with tafasitamab plus lenalidomide following disease progression on the R-mini-CHOP regimen. PEER REVIEWED ARTICLE **Peer reviewers:** Prof. Andreas Holbro, University Hospital Basel, Basel, Switzerland Prof. Christoph Renner, Hospital Hirslanden, Zurich, Switzerland Erik Aerts, Hematology Nurses & Healthcare Professionals Group, University Hospital Zurich, Zurich, Switzerland Received on January 09, 2025; accepted after peer review on March 20, 2025; published online on March 23, 2025.https://doi.org/10.36000/HBT.OH.2025.23.174 |
| spellingShingle | Alexander Meisel Ziad Kassem Daniel Turek Tanja Angelina Gradistanac Tristan de Lage Christina Züger Tafasitamab and Lenalidomide as Second-Line Treatment in an Elderly Patient with a Primary Refractory Double-Hit Diffuse Large B-Cell Lymphoma healthbook TIMES. Oncology Hematology |
| title | Tafasitamab and Lenalidomide as Second-Line Treatment in an Elderly Patient with a Primary Refractory Double-Hit Diffuse Large B-Cell Lymphoma |
| title_full | Tafasitamab and Lenalidomide as Second-Line Treatment in an Elderly Patient with a Primary Refractory Double-Hit Diffuse Large B-Cell Lymphoma |
| title_fullStr | Tafasitamab and Lenalidomide as Second-Line Treatment in an Elderly Patient with a Primary Refractory Double-Hit Diffuse Large B-Cell Lymphoma |
| title_full_unstemmed | Tafasitamab and Lenalidomide as Second-Line Treatment in an Elderly Patient with a Primary Refractory Double-Hit Diffuse Large B-Cell Lymphoma |
| title_short | Tafasitamab and Lenalidomide as Second-Line Treatment in an Elderly Patient with a Primary Refractory Double-Hit Diffuse Large B-Cell Lymphoma |
| title_sort | tafasitamab and lenalidomide as second line treatment in an elderly patient with a primary refractory double hit diffuse large b cell lymphoma |
| url | https://doi.org/10.36000/HBT.OH.2025.23.174 |
| work_keys_str_mv | AT alexandermeisel tafasitamabandlenalidomideassecondlinetreatmentinanelderlypatientwithaprimaryrefractorydoublehitdiffuselargebcelllymphoma AT ziadkassem tafasitamabandlenalidomideassecondlinetreatmentinanelderlypatientwithaprimaryrefractorydoublehitdiffuselargebcelllymphoma AT danielturek tafasitamabandlenalidomideassecondlinetreatmentinanelderlypatientwithaprimaryrefractorydoublehitdiffuselargebcelllymphoma AT tanjaangelinagradistanac tafasitamabandlenalidomideassecondlinetreatmentinanelderlypatientwithaprimaryrefractorydoublehitdiffuselargebcelllymphoma AT tristandelage tafasitamabandlenalidomideassecondlinetreatmentinanelderlypatientwithaprimaryrefractorydoublehitdiffuselargebcelllymphoma AT christinazuger tafasitamabandlenalidomideassecondlinetreatmentinanelderlypatientwithaprimaryrefractorydoublehitdiffuselargebcelllymphoma |